1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis

References

• Helmick, C. G., D. T. Felson, R. C. Lawrence, et al. 2008. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58: 15–25
   PubMed Web of Science ®Google Scholar
• Curtis, J. R., and J. A. Singh. 2011. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin. Ther. 33: 679–707
   PubMed Web of Science ®Google Scholar
• Singh, J. A., D. E. Furst, A. Bharat, et al. 2012. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64: 625–639
   PubMed Web of Science ®Google Scholar
• Alghasham, A., and Z. Rasheed. 2014. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity 47: 77–94
   PubMed Web of Science ®Google Scholar
• Katchamart, W., J. Trudeau, V. Phumethum, and C. Bombardier. 2010. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst. Rev. CD008495 . doi:10.1002/14651858.CD008495
   Google Scholar
• Rath, T., and A. Rubbert. 2010. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin. Exp. Rheumatol. 28: S52–S57
   PubMed Web of Science ®Google Scholar
• Scott, G. N., J. DuHadaway, E. Pigott, et al. 2009. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J. Immunol. 182: 7509–7517
   PubMed Web of Science ®Google Scholar
• Pigott, E., and L. Mandik-Nayak. 2012. Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice. Arthritis Rheum. 64: 2169–2178
   PubMedGoogle Scholar
• Muller, A. J., and P. A. Scherle. 2006. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6: 613–625
   PubMed Web of Science ®Google Scholar
• Prendergast, G. C., M. Y. Chang, L. Mandik-Nayak, et al. 2011. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr. Med. Chem. 18: 2257–2262
   PubMed Web of Science ®Google Scholar
• Oertelt-Prigione, S., T. K. Mao, C. Selmi, et al. 2008. Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. Autoimmunity 41: 92–99
   PubMed Web of Science ®Google Scholar
• Mellor, A. L., and D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. 4: 762–774
   Google Scholar
• Williams, R. O. 2013. Exploitation of the IDO pathway in the therapy of rheumatoid arthritis. Int. J. Tryptophan Res. 6: 67–73
   PubMedGoogle Scholar
• Xu, H., T. B. Oriss, M. Fei, et al. 2008. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl. Acad. Sci. U.S.A. 105: 6690–6695
   PubMed Web of Science ®Google Scholar
• von Bubnoff, D., and T. Bieber. 2012. The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy. Allergy 67: 718–725
   PubMed Web of Science ®Google Scholar
• Schroecksnadel, K., C. Winkler, C. Duftner, et al. 2006. Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin. Rheumatol. 25: 334–337
   PubMed Web of Science ®Google Scholar
• Schroecksnadel, K., S. Kaser, M. Ledochowski, et al. 2003. Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J. Rheumatol. 30: 1935–1939
   PubMed Web of Science ®Google Scholar
• Kouskoff, V., A. S. Korganow, V. Duchatelle, et al. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87: 811–822
   PubMed Web of Science ®Google Scholar
• Korganow, A. S., H. Ji, S. Mangialaio, et al. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10: 451–461
   PubMed Web of Science ®Google Scholar
• Kyburz, D., D. A. Carson, and M. Corr. 2000. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum. 43: 2571–2577
   PubMed Web of Science ®Google Scholar
• Ohmura, K., L. T. Nguyen, R. M. Locksley, et al. 2005. Interleukin-4 can be a key positive regulator of inflammatory arthritis. Arthritis Rheum. 52: 1866–1875
   PubMed Web of Science ®Google Scholar
• Wu, H. J., H. Sawaya, B. Binstadt, et al. 2007. Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. J. Exp. Med. 204: 1911–1922
   PubMed Web of Science ®Google Scholar
• Pincus, T., G. Ferraccioli, T. Sokka, et al. 2002. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford). 41: 1346–1356
   PubMed Web of Science ®Google Scholar
• Braun, J., and R. Rau. 2009. An update on methotrexate. Curr. Opin. Rheumatol. 21: 216–223
   PubMed Web of Science ®Google Scholar
• Neurath, M. F., K. Hildner, C. Becker, et al. 1999. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115: 42–55
   PubMed Web of Science ®Google Scholar
• Asanuma, Y., K. Nagai, M. Kato, et al. 2002. Weekly pulse therapy of methotrexate improves survival compared with its daily administration in MRL/lpr mice. Eur. J. Pharmacol. 435: 253–258
   PubMed Web of Science ®Google Scholar
• Wessels, J. A., T. W. Huizinga, and H. J. Guchelaar. 2008. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 47: 249–255
   PubMed Web of Science ®Google Scholar
• Tian, H., and B. N. Cronstein. 2007. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 65: 168–173
   PubMedGoogle Scholar
• Huang, C. C., P. C. Hsu, Y. C. Hung, et al. 2005. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis 10: 895–907
   PubMed Web of Science ®Google Scholar
• Andersson, S. E., L. H. Johansson, K. Lexmuller, and G. M. Ekstrom. 2000. Anti-arthritic effect of methotrexate: is it really mediated by adenosine? Eur. J. Pharm. Sci. 9: 333–343
   PubMed Web of Science ®Google Scholar
• Baban, B., P. Chandler, D. McCool, et al. 2004. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod. Immunol. 61: 67–77
   PubMed Web of Science ®Google Scholar
• Muller, A. J., J. B. DuHadaway, P. S. Donover, et al. 2005. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11: 312–319
   PubMed Web of Science ®Google Scholar
• Mandik-Nayak, L., B. T. Wipke, F. F. Shih, et al. 2002. Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node. Proc. Natl. Acad. Sci. U.S.A. 99: 14368–14373
   PubMed Web of Science ®Google Scholar
• Chen, R., L. Lowe, J. D. Wilson, et al. 1999. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin. Chem. 45: 1693–1694
   PubMed Web of Science ®Google Scholar
• Elshal, M. F., and J. P. McCoy. 2006. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38: 317–323
   PubMed Web of Science ®Google Scholar
• Albrecht, K., and U. Muller-Ladner. 2010. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin. Exp. Rheumatol. 28: S95–S101
   PubMed Web of Science ®Google Scholar
• Gerards, A. H., S. de Lathouder, E. R. de Groot, et al. 2003. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford). 42: 1189–1196
   PubMed Web of Science ®Google Scholar
• de Lathouder, S., A. H. Gerards, B. A. Dijkmans, and L. A. Aarden. 2004. Two inhibitors of DNA-synthesis lead to inhibition of cytokine production via a different mechanism. Nucleosides Nucleotides Nucleic Acids 23: 1089–1100
   PubMed Web of Science ®Google Scholar
• Kraan, M. C., T. J. Smeets, M. J. van Loon, et al. 2004. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann. Rheum. Dis. 63: 1056–1061
   PubMed Web of Science ®Google Scholar
• Chan, E. S., and B. N. Cronstein. 2010. Methotrexate – how does it really work? Nat. Rev. Rheumatol. 6: 175–178
   PubMed Web of Science ®Google Scholar
• Montesinos, M. C., J. S. Yap, A. Desai, et al. 2000. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43: 656–663
   PubMed Web of Science ®Google Scholar
• Szabo, C., G. S. Scott, L. Virag, et al. 1998. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. 125: 379–387
   PubMed Web of Science ®Google Scholar
• Heby, O. 1981. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 19: 1–20
   PubMed Web of Science ®Google Scholar
• Upchurch, K. S., and J. Kay. 2012. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 51 Suppl 6: vi28–vi36
   PubMed Web of Science ®Google Scholar
• Jia, L., K. Schweikart, J. Tomaszewski, et al. 2008. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem. Toxicol. 46: 203–211
   PubMed Web of Science ®Google Scholar
• Soliman, H., M. Mediavilla-Varela, and S. Antonia. 2010. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J. (Sudbury, Mass) 16: 354–359
   PubMed Web of Science ®Google Scholar
• Soliman, H. H., S. Antonia, D. Sullivan, et al. 2009. Overcoming tumor antigen anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J. Clin. Oncol. 27: Abstract 3004
   Web of Science ®Google Scholar
• Soliman, H. H., S. E. Minton, H. S. Han, et al. 2013. A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. J. Clin. Oncol. Suppl Abstract 3069
   PubMed Web of Science ®Google Scholar
• Gonen, N., and Y. G. Assaraf. 2012. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist. Updat. Rev. Commentaries Antimicrob. Anticancer Chemother. 15: 183–210
   Google Scholar
• Blits, M., G. Jansen, Y. G. Assaraf, et al. 2013. Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 65: 2791–2802
   PubMed Web of Science ®Google Scholar
• Salinas-Carmona, M. C., L. I. Perez, K. Galan, and A. V. Vazquez. 2009. Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB/c mice. Autoimmunity 42: 537–544
   PubMed Web of Science ®Google Scholar
• Berti, E., G. Vannucci, C. Lunardi, et al. 2013. Identification of autoantibodies against inner ear antigens in a cohort of children with idiopathic sensorineural hearing loss. Autoimmunity 46: 525–530
   PubMed Web of Science ®Google Scholar
• Metz, R., S. Rust, J. B. Duhadaway, et al. 2012. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1: 1460–1468
   PubMed Web of Science ®Google Scholar
• Mellor, A. L., B. Baban, P. Chandler, et al. 2003. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171: 1652–1655
   PubMed Web of Science ®Google Scholar
• Fallarino, F., C. Vacca, C. Orabona, et al. 2002. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int. Immunol. 14: 65–68
   PubMed Web of Science ®Google Scholar
• Hou, D. Y., A. J. Muller, M. D. Sharma, et al. 2007. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67: 792–801
   PubMed Web of Science ®Google Scholar